With their bioprinting technology, Canada’s Aspect Biosystems is working towards the noble goal of “a future where doctors determine which drugs work for their patients before prescribing them, where animals are no longer needed for the development of new therapeutics, and where lifesaving transplant organs are created, not harvested.” This is a goal not dissimilar to the only publicly traded bioprinting company, Organovo, and, while Organovo just raked $40 million through a secondary stock offering, Aspect Biosytems is raising its own funds through a recent “oversubscribed” seed round from local Vancouver Angel investors.…
The original post New Bioprinting Tech to be Developed by Aspect Biosystems with Seed Funding appeared first on 3D Printing Industry.
